Biotechnology - Neurological, Pricing

Filter

Current filters:

NeurologicalPricing

Popular Filters

Genzyme gains UK NICE backing for second MS drug Lemtrada

Genzyme gains UK NICE backing for second MS drug Lemtrada

28-05-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

AubagioBiotechnologyGenzymeLemtradaNeurologicalPricingRegulationSanofiUK

NICE recommends Sanofi’s Aubagio as new treatment option for MS

NICE recommends Sanofi’s Aubagio as new treatment option for MS

22-01-2014

In final guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

AubagioBiotechnologyGenzymeNeurologicalNorthern EuropePricingRegulationSanofiUK

UK’s NICE calls for more info on Sanofi’s Lemtrada in draft guidance

UK’s NICE calls for more info on Sanofi’s Lemtrada in draft guidance

05-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

BiotechnologyEuropeGenzymeLemtradaNeurologicalPricingRegulationSanofiUK

UK's NICE calls for more information on MS treatment Aubagio

18-09-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

AubagioBiotechnologyEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofi

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada

02-11-2012

US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

Reimbursement outlook for DMT Alzheimer's therapies in Europe

06-06-2012

Emerging potentially disease-modifying therapies (DMTs) for Alzheimer's disease will likely be reimbursed…

BiotechnologyEuropeMarkets & MarketingNeurologicalPharmaceuticalPricing

Back to top